Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria

AIDS Behav. 2022 May;26(5):1504-1516. doi: 10.1007/s10461-021-03504-5. Epub 2022 Jan 8.


HIV remission trials often require temporary stopping of antiretroviral therapy (ART)-an approach called analytic treatment interruption (ATI). Trial designs resulting in viremia raise risks for participants and sexual partners. We conducted a survey on attitudes about remission trials, comparing ART resumption criteria (lower-risk "time to rebound" and higher-risk "sustained viremia") among participants from an acute HIV cohort in Thailand. Analyses included Wilcoxon-Ranks and multivariate logistic analysis. Most of 408 respondents supported ATI trials, with slightly higher approval of, and willingness to participate in, trials using time to rebound versus sustained viremia criteria. Less than half of respondents anticipated disclosing trial participation to partners and over half indicated uncertainty or unwillingness about whether partners would be willing to use PrEP. Willingness to participate was higher among those who rated higher trial approval, lower anticipated burden, and those expecting to make the decision independently. Our findings support acceptability of ATI trials among most respondents. Participant attitudes and anticipated behaviors, especially related to transmission risk, have implications for future trial design and informed consent.

Keywords: Analytic treatment interruption; Attitudes; Remission; Transmission; Willingness to participate.

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • Attitude
  • Causality
  • HIV Infections* / drug therapy
  • Humans
  • Surveys and Questionnaires
  • Viral Load
  • Viremia* / drug therapy


  • Anti-Retroviral Agents